 CAMBRIDGE, Mass., June 03, 2021 GLOBE NEWSWIRE -- Evelo Biosciences, Inc. Nasdaq: EVLO, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expansion of the Leadership Team, the Evelo Board of Directors has approved an inducement equity plan. 